---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-121635"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-12-16T23:59:59+00:00"
generated_at: "2026-05-16T13:00:15.952258+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma grants options and RSUs to five executives with $2.33 exercise price

## Summary
- Compensation Committee approved equity grants to CEO, CFO, CSO, CMO, and COO on December 12, 2025.
- CEO Iain Dukes receives 147,771 options + 36,943 RSUs; CFO Charles Parker receives 61,571 options + 15,393 RSUs.
- CSO C. David Pauza receives 73,886 options + 18,471 RSUs; CMO Robert Redfield receives 65,676 options + 16,419 RSUs.
- COO Nikolay Savchuk receives 65,676 options + 16,419 RSUs; all options have $2.33 strike, 10-year term, vest in 1 year.
- Grants made under the Amended and Restated 2021 Incentive Compensation Plan.

## SEC filing metadata
- accession: 0001104659-25-121635
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925121635/0001104659-25-121635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925121635/tm2533625d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-121635
- JSON: https://secwatch.observer/filing/0001104659-25-121635.json
- Plain text: https://secwatch.observer/filing/0001104659-25-121635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.